S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
- Status
- WITHDRAWN
- Phase
- PHASE2
Clinical Trials Related to Bortezomib
Related studies linked through entity extraction aliases.
A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Retreatment Study With Bortezomib for Multiple Myeloma
- Status
- COMPLETED
- Phase
- N/A
Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Observational Study of the Effects Intravenous Bortezomib Has on Osteoblast (Cell That is Responsible for Bone Formation) Activity in Multiple Myeloma Patients.
- Status
- COMPLETED
- Phase
- N/A
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE3
Quality of Life in Multiple Myeloma Patients Treated With Bortezomib
- Status
- COMPLETED
- Phase
- N/A
Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma
- Status
- COMPLETED
- Phase
- PHASE1
IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib (Velcade) - Regulatory Post Marketing Surveillance (PMS)
- Status
- COMPLETED
- Phase
- N/A
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
- Status
- TERMINATED
- Phase
- PHASE3
EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Presurgery Bortezomib for Recurrent Malignant Gliomas Followed by Postop Bortezomib & Temozolomide
- Status
- COMPLETED
- Phase
- PHASE2
Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients
- Status
- TERMINATED
- Phase
- PHASE2
Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Effect of Combination of Bortezomib/Dexamethasone/Zoledronic Acid on Bone Disease in Patients With Multiple Myeloma Relapsed After 1-3 Prior Lines of Therapy
- Status
- COMPLETED
- Phase
- PHASE2